Dose-Dense Docetaxel-Cyclophosphamide and Epirubicin-Cisplatin(ddDCEP): Analysis of an Alternative Platinum-Containing Regimen in 116 Patients with Early Triple Negative Breast Cancer

Singh, Ashish; Georgy, Josh Thomas; Joel, Anjana; Thumaty, Divya Bala; John, Ajoy Oommen; Ramnath, Nithya; George, Tarun K; Sharma, Parth; Patole, Shalom; Rebekah, Grace; Sigamani, Elanthenral; Manipadam, Marie Therese; Cherian, Anish Jacob; Abraham, Deepak Thomas; Paul, Mazhuvanchary Jacob; Balakrishnan, Rajesh; Sebastian, Patricia; Backianathan, Selvamani; Chacko, Raju Titus

doi:10.6084/m9.figshare.24541053.v1

icnv_a_2278048_sm0435.pdf (864.52 kB)

Dose-Dense Docetaxel-Cyclophosphamide and Epirubicin-Cisplatin(ddDCEP): Analysis of an Alternative Platinum-Containing Regimen in 116 Patients with Early Triple Negative Breast Cancer

journal contribution

posted on 2023-11-10, 06:20 authored by Ashish Singh, Josh Thomas Georgy, Anjana Joel, Divya Bala Thumaty, Ajoy Oommen John, Nithya Ramnath, Tarun K George, Parth Sharma, Shalom Patole, Grace Rebekah, Elanthenral Sigamani, Marie Therese Manipadam, Anish Jacob Cherian, Deepak Thomas Abraham, Mazhuvanchary Jacob Paul, Rajesh Balakrishnan, Patricia Sebastian, Selvamani Backianathan, Raju Titus Chacko

We assessed the efficacy, tolerability, and cost-effectiveness of a novel neoadjuvant regimen comprising docetaxel-cyclophosphamide alternating with epirubicin-cisplatin (ddDCEP) administered biweekly for 16 weeks in 116 patients with early triple-negative breast cancer. This regimen achieved a high pathological complete response (ypT0/TisN0) rate of 55.2% and favorable survival outcomes (30-month event-free survival, 91.2%; overall survival, 97%). Febrile neutropenia was observed in 4.3% of patients, and 98% completed at least six of eight cycles. ddDCEP was more cost-effective than contemporary carboplatin-based regimens. This novel approach offers an economically viable and effective alternative to current chemoimmunotherapy regimens, and merits further investigation.